AstraZeneca touts enhanced protection with COVID-19 antibody in immunocompromised people

16 May 2024
firstwordpharma.com
Clinical ResultPhase 3Emergency Use Authorization
AstraZeneca on Thursday said the long-acting antibody sipavibart significantly reduced the incidence of symptomatic COVID-19 compared with placebo or its predecessor antibody cocktail Evusheld (tixagevimab/cilgavimab) in a Phase III pre-exposure prophylaxis study involving immunocompromised individuals — a population that accounts for nearly a quarter of cases with worse outcomes.
With the positive readout, Astrazeneca is poised to compete against Invivyd's Pemgarda (pemivibart), which recently secured an emergency-use authorisation (EUA) in the US for pre-exposure COVID-19 prophylaxis of immunocompromised patients.
“Immunocompromised patients currently have limited or no options for COVID-19 protection…despite often being fully vaccinated,” noted Iskra Reic, EVP of vaccines and immune therapies at AstraZeneca, adding that “sipavibart has the potential to prevent COVID-19” in this vulnerable population.
The SUPERNOVA trial randomised 3335 immunocompromised participants to receive either a single 300mg intramuscular dose of sipavibart or a comparator consisting of placebo or Evusheld. The participants included individuals aged 12 years and above, at risk of not adequately responding to active immunisation and at high risk for developing severe COVID-19.
Superior protection across variants
Top-line results showed sipavibart met the study’s dual primary endpoints — reducing the risk of symptomatic disease from any SARS-CoV-2 variant and the risk of infections from variants not harbouring the F456L mutation, relative to the comparator. AstraZeneca noted that the protection offered by sipavibart was consistent across the evolving variant landscape throughout the study.
In terms of safety, the antibody was well tolerated, with a comparable adverse-event profile between the sipavibart and control arms. Detailed findings will be unveiled at a forthcoming medical conference.
AstraZeneca’s Evusheld lost its EUA for pre-exposure prophylaxis in the US early last year, after failing to neutralise circulating SARS-CoV-2 variants in vitro. The drugmaker now intends to engage with regulators to outline the approval process for sipavibart, looking to regain its position in the COVID-19 prophylactics market.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.